Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives Average Recommendation of “Moderate Buy” from Brokerages

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) has earned a consensus recommendation of “Moderate Buy” from the nineteen brokerages that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and fourteen have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $970.57.

A number of equities analysts recently weighed in on the company. Barclays upped their price target on Regeneron Pharmaceuticals from $935.00 to $1,020.00 and gave the stock an “overweight” rating in a report on Tuesday, January 23rd. StockNews.com upgraded Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Friday, April 12th. Bank of America increased their price objective on Regeneron Pharmaceuticals from $710.00 to $720.00 and gave the company an “underperform” rating in a research note on Friday, April 12th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Monday. Finally, Morgan Stanley increased their target price on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the company an “overweight” rating in a report on Wednesday, March 13th.

Regeneron Pharmaceuticals Stock Up 0.8 %

Shares of REGN stock opened at $901.19 on Friday. Regeneron Pharmaceuticals has a 1-year low of $684.80 and a 1-year high of $998.33. The stock’s fifty day moving average price is $955.19 and its 200 day moving average price is $890.52. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.69 and a quick ratio of 4.94. The company has a market cap of $98.91 billion, a price-to-earnings ratio of 25.93, a price-to-earnings-growth ratio of 2.62 and a beta of 0.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Friday, February 2nd. The biopharmaceutical company reported $11.86 EPS for the quarter, topping analysts’ consensus estimates of $10.73 by $1.13. The company had revenue of $3.43 billion during the quarter, compared to analysts’ expectations of $3.29 billion. Regeneron Pharmaceuticals had a return on equity of 17.61% and a net margin of 30.14%. The firm’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $10.96 EPS. On average, research analysts expect that Regeneron Pharmaceuticals will post 38.18 earnings per share for the current fiscal year.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total transaction of $95,422.00. Following the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $954.22, for a total value of $95,422.00. Following the sale, the director now owns 18,382 shares of the company’s stock, valued at approximately $17,540,472.04. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Marion Mccourt sold 1,000 shares of the business’s stock in a transaction on Monday, February 5th. The shares were sold at an average price of $934.71, for a total value of $934,710.00. Following the completion of the transaction, the executive vice president now owns 13,789 shares of the company’s stock, valued at $12,888,716.19. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 13,729 shares of company stock valued at $13,124,641. 8.83% of the stock is owned by corporate insiders.

Institutional Trading of Regeneron Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Sunbelt Securities Inc. purchased a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $25,000. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth about $26,000. West Paces Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 23 shares during the period. O Dell Group LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $27,000. Finally, Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at approximately $31,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.